MedTrace Logo

Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

NCT02684578 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2023-06-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

Conditions

  • Age-Related Macular Degeneration
  • Macular Degeneration, Age-Related
  • Dry Macular Degeneration
  • Geographic Atrophy

Interventions

DRUG

Metformin

Sponsors & Collaborators

  • San Francisco Veterans Affairs Medical Center

    collaborator FED

  • VA Palo Alto Health Care System

    collaborator FED

  • University of California, Davis

    collaborator OTHER

  • University of California, San Diego

    collaborator OTHER

  • Northwestern University

    collaborator OTHER

  • University of Illinois at Chicago

    collaborator OTHER

  • Retinal Consultants Medical Group

    collaborator OTHER

  • Retina Health Center

    collaborator INDUSTRY

  • California Retina Consultants

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • University of California, San Francisco

    lead OTHER

Principal Investigators

  • Jay M Stewart, MD · University of California, San Francisco

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2022-04-30
Completion
2022-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02684578 on ClinicalTrials.gov